Maahs Suzanne, Leclair Denise, Gomez-Mancilla Baltazar, Kiluk Brian D, Muthusamy Velusamy Shanmuganathan, Banerjee Partha S, Dasgupta Shyamashree, Waye Katherine M
Novartis Biomedical Research, Cambridge, MA, United States.
Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Front Psychiatry. 2024 Feb 29;15:1230699. doi: 10.3389/fpsyt.2024.1230699. eCollection 2024.
Cocaine use disorder (CUD) is characterized by the continued use of cocaine despite serious impacts on life. This study focused on understanding the perspective of individuals with current CUD, individuals in CUD remission, and their supporters regarding current therapies, future therapies, and views on clinical trials for CUD.
The online bulletin board (OBB) is a qualitative tool where participants engage in an interactive discussion on a virtual forum. Following completion of a screening questionnaire to determine eligibility, individuals in CUD remission and their supporters logged in to the OBB and responded to questions posed by the moderator. Individuals with current CUD participated in a one-time virtual focus group.
All individuals with current CUD and 94% of those in CUD remission reported a diagnosis consistent with CUD or substance use disorder during screening. Individuals with current CUD and their supporters were recruited from the United States (US). Individuals in CUD remission were recruited from five countries, including the US. Individuals with current CUD reported hesitation about seeking treatment due to stigma, a lack of privacy, and being labeled as a drug seeker; barriers to therapy included time, cost, and a lack of privacy. Participants wanted a safe therapy to stop cravings and withdrawal symptoms. Seven clinical trial outcomes, including long-term abstinence and craving control, were suggested based on collected insights.
This study can help inform the design of clinical trials and emphasize the need for effective, safe, and accessible therapies. Recruiting participants will require significant trust building.
可卡因使用障碍(CUD)的特征是尽管对生活有严重影响仍持续使用可卡因。本研究着重于了解当前患有CUD的个体、处于CUD缓解期的个体及其支持者对当前治疗方法、未来治疗方法以及CUD临床试验的看法。
在线公告板(OBB)是一种定性工具,参与者在虚拟论坛上进行互动讨论。在完成筛选问卷以确定资格后,处于CUD缓解期的个体及其支持者登录OBB并回答主持人提出的问题。当前患有CUD的个体参加了一次虚拟焦点小组。
所有当前患有CUD的个体以及94%处于CUD缓解期的个体在筛查期间报告的诊断与CUD或物质使用障碍一致。当前患有CUD的个体及其支持者来自美国。处于CUD缓解期的个体来自包括美国在内的五个国家。当前患有CUD的个体报告称,由于耻辱感、缺乏隐私以及被贴上寻求药物者的标签,他们在寻求治疗时有所犹豫;治疗的障碍包括时间、成本和缺乏隐私。参与者希望有一种安全的治疗方法来停止渴望和戒断症状。根据收集到的见解,提出了七个临床试验结果,包括长期戒断和渴望控制。
本研究有助于为临床试验的设计提供信息,并强调需要有效、安全且可及的治疗方法。招募参与者需要建立重大的信任。